Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • HS-110
    • HS-130
    • Expanded Access
    • Scientific Publications
  • Investors
  • News & Media
  • Careers
  • Contact

News Releases

Heat Biologics Announces Planned Transfer to the NYSE American

Feb 2, 2022

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Jan 31, 2022

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Jan 12, 2022

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

Dec 21, 2021

Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Nov 30, 2021

Heat Biologics Provides Third Quarter 2021 Business Update

Nov 10, 2021

Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy

Oct 6, 2021

Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th

Sep 15, 2021

Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 9, 2021

Heat Biologics to Provide Corporate Update

Aug 30, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...29
    NightHawk Biosciences

    OUR ECOSYSTEM

    SkunkWorx Bio
    Heat Biologics
    Elusys Therapeutics Inc.
    Pelican Therapeutics
    Scorpion Biological Services
    © 2022 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn